They also recommended that future EHRs be “designed to enable postmarketing surveillance of treatment indications and treatment outcomes to monitor the safety of on-and off-label use of drugs.”
1. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-990.
2. Agency for Healthcare Research and Quality (AHRQ). Off-label drugs: What you need to know. Available at: http://www.ahrq.gov/patients-consumers/patient-involvement/off-label-drug-usage.html. Accessed: December 2, 2015.
3. Eguale T, Buckeridge DL, Verma A, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2015 Nov 2:1-9.
4. Good CB, Gellad WF. Off-label drug use and adverse drug events: turning up the heat on off-label prescribing. JAMA Intern Med. 2015 Nov 2:1-2.
5. Henning PJ. F.D.A.’s ‘Off-Label’ Drug Policy Leads to Free-Speech Fight. Available at: http://www.nytimes.com/2015/08/11/business/dealbook/fdas-off-label-drug-policy-leads-to-free-speech-fight.html?_r=0. Accessed: December 2, 2015.